Evidence map›Paper›PMID 38003911›Full record

ArticleJournal of personalized medicine2023

A Linear Predictor Based on FTIR Spectral Biomarkers Improves Disease Diagnosis Classification: An Application to Multiple Sclerosis.

Francesca Condino, Maria Caterina Crocco, Domenico Pirritano, Alfredo Petrone, Francesco Del Giudice, Rita Guzzi

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Francesca CondinoDepartment of Economics, Statistics and Finance "Giovanni Anania", University of Calabria, 87036 Rende, Italy.ORCID 0000-0001-7814-7799
Maria Caterina CroccoSTAR Research Infrastructure, University of Calabria, 87036 Rende, Italy.ORCID 0000-0002-9923-2754
Domenico PirritanoSOC Neurologia, Azienda Ospedaliero-Universitaria Renato Dulbecco, 88100 Catanzaro, Italy.
Alfredo PetroneUOC Neurologia, Azienda Ospedaliera dell'Annunziata, 87100 Cosenza, Italy.
Francesco Del GiudiceUOC Neurologia, Azienda Ospedaliera dell'Annunziata, 87100 Cosenza, Italy.
Rita GuzziSTAR Research Infrastructure, University of Calabria, 87036 Rende, Italy.ORCID 0000-0001-6769-3399

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a neurodegenerative disease of the central nervous system that can lead to long-term disability. The diagnosis of MS is not simple and requires many instrumental and clinical tests. Sampling easily collected biofluids using spectroscopic approaches is becoming of increasing interest in the medical field to integrate and improve diagnostic procedures. Here we present a statistical approach where we combine a number of spectral biomarkers derived from the ATR-FTIR spectra of blood plasma samples of healthy control subjects and MS patients, to obtain a linear predictor useful for discriminating between the two groups of individuals. This predictor provides a simple tool in which the contribution of different molecular components is summarized and, as a result, the sensitivity (80%) and specificity (93%) of the identification are significantly improved compared to those obtained with typical classification algorithms. The strategy proposed can be very helpful when applied to the diagnosis of diseases whose presence is reflected in a minimal way in the analyzed biofluids (blood and its derivatives), as it is for MS as well as for other neurological disorders.

Indexed as

ATR-FTIRdiscriminationlogistic regressionmultiple sclerosismultivariate analysisplasma

Identifiers

PMID38003911
PMCPMC10672539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.